On January 27, 2026, the U.S. Centers for Medicare & Medicaid Services announced that Pfizer’s branded drugs were chosen for the third cycle of the Medicare Drug Price Negotiation Program. The program, established under the Inflation Reduction Act, allows the federal government to negotiate prices for high‑cost prescription drugs covered by Medicare Parts B and D, with the third cycle expanding to include Part B drugs for the first time.
The selected drugs will be negotiated in 2026, and the resulting price reductions will take effect on January 1, 2028. The program’s first two cycles already produced significant savings—estimated at $8.5 billion in net covered prescription drug costs if the second‑cycle prices had been in effect in 2024, representing a 36 % reduction in aggregate net spending.
Pfizer’s portfolio in the third cycle includes Tofacitinib (Xeljanz and Xeljanz XR), a Janus kinase inhibitor used for rheumatoid arthritis and other autoimmune conditions. The inclusion of this drug, along with other unnamed Pfizer products, signals that the company will face intensified pricing pressure from Medicare, a payer that accounts for a sizable portion of its revenue base.
Historically, Medicare negotiations have led to price cuts ranging from 10 % to 30 % for named products. For Pfizer, the impact of past cycles has been material: the second‑cycle reductions would have lowered the company’s net drug costs by billions, tightening margins and compressing revenue projections. The upcoming negotiations therefore carry the risk of similar margin compression, especially for high‑cost specialty drugs that are heavily priced for Medicare beneficiaries.
Pfizer’s recent financial performance underscores the potential significance of the negotiations. In Q3 2025, the company reported revenue of $16.7 billion, a 7 % year‑over‑year decline driven by lower COVID‑19 product sales, while its non‑COVID portfolio grew 4 % operationally. Adjusted diluted earnings per share were $0.87, beating consensus estimates of $0.79 by $0.08. Management cited disciplined cost control and a favorable mix of high‑margin specialty products as key drivers of the earnings beat.
The company reaffirmed its FY2025 revenue guidance of $61.0 billion to $64.0 billion and maintained an adjusted diluted EPS guidance of $3.00 to $3.15, reflecting confidence in its core business despite the pricing headwind. Chief Executive Officer Albert Bourla emphasized that the company remains focused on commercial execution and strategic investments, while Chief Financial Officer David Denton highlighted the importance of maintaining financial discipline amid the upcoming negotiations.
Analysts have expressed mixed views on the Medicare announcement. While some see the pricing pressure as a potential drag on future earnings, others note that Pfizer’s diversified portfolio and strong non‑COVID growth provide a buffer. The company’s guidance remains unchanged, but the negotiations introduce a new risk factor that could influence future profitability and investor expectations.
The inclusion of Pfizer’s drugs in the Medicare negotiation cycle represents a significant regulatory event that could reshape the company’s pricing strategy and impact its financial outlook. Investors will likely monitor the negotiation outcomes closely, as the resulting price reductions could materially compress margins and alter revenue projections for the 2026 fiscal year.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.